CoChat

Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action

Open access
Hoenigl, Martin, Sprute, Rosanne, Arastehfar, Amir, Perfect, John R., Lass-Flörl, Cornelia, Bellmann, Romuald, Prattes, Juergen, Thompson, George R., Wiederhold, Nathan P., Al Obaidi, Mohanad M., Willinger, Birgit, Arendrup, Maiken C., Koehler, Philipp, Oliverio, Matteo, Egger, Matthias, Schwartz, Ilan S., Cornely, Oliver A., Pappas, Peter G., Krause, Robert · 2022 · Expert Opinion on Investigational Drugs
Cited by 45

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.

Abstract

Introduction The epidemiology of invasive Candida infections is evolving. Infections caused by non-albicans Candida spp. are increasing; however, the antifungal pipeline is more promising than ever and is enriched with repurposed drugs and agents that have new mechanisms of action. Despite progress, unmet needs in the treatment of invasive candidiasis remain, and there are still too few antifungals that can be administered orally or that have CNS penetration.Areas covered The authors shed light on those antifungal agents active against Candida that are in early- and late-stage clinical development. Mechanisms of action and key pharmacokinetic and pharmacodynamic properties are discussed. Insights are offered on the potential future roles of the investigational agents MAT-2203, oteseconazole, ATI-2307, VL-2397, NP-339, and the repurposed drug miltefosine.Expert opinion Ibrexafungerp and fosmanogepix have novel mechanisms of action and will provide effective options for the treatment of Candida infections (including those caused by multiresistant Candida spp). Rezafungin, an echinocandin with an extended half-life allowing for once weekly administration, will be particularly valuable for outpatient treatment and prophylaxis. Despite this, there is an urgent need to garner clinical data on investigational drugs, especially in the current rise of azole-resistant and multidrug-resistant Candida spp.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/13543784.2022.2086120

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 56 references

Cited by

See all 45

Metadata

Authors
Hoenigl, M., Sprute, R., Arastehfar, A., Perfect, J. R., Lass-Flörl, C., Bellmann, R., Prattes, J., Thompson, G. R., Wiederhold, N. P., Al Obaidi, M. M., Willinger, B., Arendrup, M. C., Koehler, P., Oliverio, M., Egger, M., Schwartz, I. S., Cornely, O. A., Pappas, P. G., & Krause, R.
Venue
Expert Opinion on Investigational Drugs
Published
2022-06-15
Volume
31
Issue
8
Pages
795-812
ISSN
  • 1354-3784 (ISSN-L)
  • 1744-7658
OpenAlex
W4282020832
Cited by
45
References
56
FWCI
4.54
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action. https://app.cochat.ai/papers/10.1080/13543784.2022.2086120
The paper
Hoenigl, M., Sprute, R., Arastehfar, A., Perfect, J. R., Lass-Flörl, C., Bellmann, R., Prattes, J., Thompson, G. R., Wiederhold, N. P., Al Obaidi, M. M., Willinger, B., Arendrup, M. C., Koehler, P., Oliverio, M., Egger, M., Schwartz, I. S., Cornely, O. A., Pappas, P. G., & Krause, R. (2022). Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action. Expert Opinion on Investigational Drugs. https://doi.org/10.1080/13543784.2022.2086120

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.